Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 4/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 5/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264013 | 0.95 | ADRB1 (0.53) | ADRB1HTR2CADRB2EPHX2HTR6 | |
| SCHEMBL5262144 | 0.82 | CYP2C19 (0.43) | ADRB1CYP1A2 | |
| SCHEMBL13853250 | 0.78 | ADRB1 (0.51) | ADRB1HTR2CADRB2EPHX2HTR6 | |
| SCHEMBL425929 | 0.77 | ADRB2 (0.71) | ADRB1HTR2CADRB2HTR6ADRA2A | |
| SCHEMBL526056 | 0.74 | HTR2C (0.65) | HTR2CADRB2EPHX2NCF1KDM4E | |
| SCHEMBL230177 | 0.74 | ADRB1 (1.00) | ADRB1HTR2CEPHX2HTR2BKDM4E | |
| SCHEMBL29623594 | 0.74 | HTR2C (0.65) | HTR2CADRB2EPHX2NCF1KDM4E | |
| SCHEMBL31536991 | 0.74 | ADRB1 (0.55) | ADRB1HTR2CADRB2EPHX2HTR6 | |
| Hydrochloric Acid SCHEMBL17541669 | 0.73 | ADRB1 (0.97) | ADRB1HTR2CEPHX2HTR2BKDM4E | |
| SCHEMBL7405998 | 0.70 | HTR2C (0.64) | HTR2CEPHX2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PEAKDALE MOLECULAR LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PEAKDALE MOLECULAR LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PNPO, CYP4B1, PDXK | ADRB1 1113/4885HTR2C 2537/4885ADRB2 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.